(Q44737088)

5 December 2017

title

The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs (English)

1 reference

5 December 2017

1 reference

Nease RF Jr

1

1 reference

5 December 2017

Ross JM

series ordinal

2

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 August 1995

1 reference

American Journal of Medicine

5 December 2017

published in

1 reference

5 December 2017

volume

99

1 reference

5 December 2017

issue

2

1 reference

5 December 2017

page(s)

180-189

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

5 December 2017

1 reference

Potential role of tamoxifen in prevention of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Screening for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Tamoxifen: disease prevention or disease substitution?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

The case for clinical trials of tamoxifen for prevention of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

The Markov process in medical prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Long term effects of tamoxifen on blood lipid values in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Long-term estrogen replacement therapy prevents bone loss and fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Menopausal estrogen therapy and hip fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Association of Exogenous Estrogen and Endometrial Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Risk of endometrial cancer after tamoxifen treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

7 January 2021

Tamoxifen and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Symptoms associated with tamoxifen treatment in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Hormone therapy to prevent disease and prolong life in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Use of replacement estrogens and the risk of myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

A prospective study of postmenopausal estrogen therapy and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Menopausal oestrogen therapy and protection from death from ischaemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Estrogen Replacement Therapy II: A Prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic Problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Estrogen replacement therapy and the risk of venous thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Cholesterol reduction and life expectancy. A model incorporating multiple risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Screening for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Occupational exposure to human immunodeficiency virus and hepatitis B virus: a comparative analysis of risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Probabilities of eventually developing or dying of cancer--United States, 1985.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

Cancer patient survival rates: SEER program results for 10 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980138-7

10.1016/S0002-9343(99)80138-7

7 January 2021

Identifiers

DOI

1 reference

5 December 2017

1 reference